CBI books pharma firm directors, officials of Dubai, Patial-based companies in Rs621 cr bank fraud
It is alleged that the accused defrauded the Punjab and Sindh Bank and four other banks of the consortium to the tune of Rs621 crore by diversion and siphoning off the loan
New Delhi: The CBI has registered a case against Surya Pharmaceuticals Ltd, its directors and officials of three companies based in Dubai and Patiala for allegedly cheating a consortium of five banks to the tune of Rs621 crore, officials said on Tuesday.
A case has been registered on charges of criminal conspiracy, cheating, forgery under the provisions of the Prevention of Corruption Act against Surya Pharmaceutical, its promoters and directors Rajeev Goel and Alka Goel. Pramod Aggarwal, director of Dubai-based Kobian Pvt. Ltd and proprietor of Nimbus FZE, and Suhail Goel, director of Patiala-based Emsons Organic Ltd. have also been booked.
“Searches were conducted today at seven places—two each in Delhi, Patiala and Chandigarh and one in Panchkula—at the offices and residences of the accused which led to the recovery of certain documents,” the CBI spokesperson said here.
It is alleged that the accused defrauded the Punjab and Sindh Bank and four other banks of the consortium to the tune of about Rs621 crore by diversion and siphoning off the loan through its sister concerns and not utilizing the credit for the purpose it was sanctioned i.e., manufacturing of pharmaceuticals, the spokesperson said.
- Taiwan takes India to WTO’s safeguard committee on solar duty
- ONGC Videsh slapped with ₹7,666 crore service tax demand
- Francois Hollande’s claim adds new twist to Rafale deal row
- RBI releases guidelines on co-origination of loans by banks, non-deposit taking NBFCs
- Tata’s UK steel plant warns it needs bigger profits to survive
Editor's Picks »
- India’s renewable energy sector hits a milestone but loses speed
- All eyes now on share swap ratio in this mega bank merger
- Jet Privilege can actually get higher valuation than Jet Airways
- Profitability of cement firms to take a hit due to weak prices, high costs
- Pidilite’s shares hold their ground despite weak rupee and rising crude